Angiotensin Converting Enzymes (ACE) Inhibitors Market Size to Exceed USD 13,179.7 Mn by 2032

The Angiotensin Converting Enzymes (ACE) Inhibitors Market, estimated at USD 9,000.3 Mn in 2025, is expected to exhibit a CAGR of 5.6% and reach USD 13,179.7 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Rising prevalence of hypertension across the globe is a significant factor driving the global angiotensin converting enzymes (ACE) inhibitors market growth. Hypertension is a major health issue worldwide, and is listed as the leading risk factor for mortality by the World Health Organization. According to WHO Data, in 2025,  around 1.28 billion people worldwide suffered from hypertension. This large patient pool requires effective treatment and management of hypertension on a regular basis to control blood pressure levels and reduce cardiovascular risks.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market– Impact of Coronavirus (COVID-19) Pandemic

COVID-19 pandemic and consequent lockdowns in various countries across the globe impacted the financial status of businesses across all sectors, including the private healthcare sector. COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.

The COVID-19 pandemic had a notably negative impact on the global angiotensin converting enzyme (ACE) inhibitors market. ACE inhibitors are a class of drugs that are commonly used to treat conditions like hypertension, heart failure, and kidney problems. During the initial phases of the pandemic, there were concerns and discussions about whether ACE inhibitors could potentially worsen COVID-19 outcomes due to their impact on the renin-angiotensin-aldosterone system (RAAS), which the virus was known to interact with. This uncertainty led to some patients discontinuing or altering their use of ACE inhibitors without proper medical guidance, causing disruptions in treatment plans and medication adherence. Furthermore, the pandemic resulted in significant disruptions in healthcare services globally. Lockdowns, restrictions, and overwhelmed healthcare systems led to reduced routine medical visits, delayed elective procedures, and disruptions in the supply chain for pharmaceuticals, including ACE inhibitors. These factors collectively impacted the demand, supply, and accessibility of ACE inhibitors in various regions.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Key Developments

On May 3, 2025, Boehringer Ingelheim, one of the the global biopharmaceutical companies, launched a new US$ 315 Mn (285 million euro) plant in  Germany.  The pharmaceutical company wants to ensure long-term capability for producing novel chemical entities, and this facility is part of that effort.

On September 23, 2025, Merck Group, a pharmaceutical company announced the expansion of its manufacturing capabilities in Molsheim, France, with an investment of more than US$ 129.1 Mn (€130 Mn). The expansion will help the company to achieve its target of increasing Merck Group’s sales to around US$ 26.9 Bn (€25 Bn) by 2025.

In September 2025, AstraZeneca, one of the research-based biopharmaceutical company announced its plan to invest US$ 360 Mn in advanced manufacturing facility in Ireland. The new plant will allow for late-stage development and early commercial supply.

Browse 29 Market Data Tables and 25 Figures spread through 163 Pages and in-depth TOC on “Global Angiotensin Converting Enzymes (ACE) Inhibitors Market”- Forecast to 2032, Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs (Benazepril, Perindopril, Trandfolapril, Captopril, Enalapril, Lisinopril, and Others (Ramipril, etc.)), By Indication (Hypertension, Coronary Artery Disease, Heart Failure, Chronic Kidney Disease, Scleroderma and Others (Migraine, etc.)), By Route of Administration (Oral and Injectable),  By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/angiotensin-converting-enzymes-ace-inhibitors-market-2746

Growing awareness about cardiovascular diseases such as hypertension and congestive heart failure has led to increased focus on their prevention and management. Angiotensin converting enzyme (ACE) inhibitors are widely recommended as one of the front-line treatments for such conditions. As people become more informed about cardiovascular health risks, the demand for ACE inhibitors is rising substantially. Various health initiatives by bodies like the WHO have emphasized on creating awareness about CVDs through community outreach programs, social media campaigns, and group discussions targeting at-risk demographics. This has led to more people getting themselves regularly screened and seeking lifestyle and medication interventions. According to the data published by WHO, in June 2025, cardiovascular diseases currently account for over 17 million deaths annually, with over 75% of these deaths occurring in low and middle income countries.  It is anticipated that more demographic segments will begin utilizing medications like ACE inhibitors for chronic disease management sooner as health education becomes more widely accepted worldwide.

Key Takeaways of the Global Angiotensin Converting Enzymes (ACE) Inhibitors Market:

• Global angiotensin converting enzymes (ACE) inhibitors market is expected to exhibit a CAGR of 5.6% during the forecast period, due to increased acceptance and more widespread adoption of ACE inhibitors among cardiologists. While initially prescribed mainly for hypertension, newer clinical evidence revealsACE inihibitors’ diverse benefits such as reduction in risks of heart attack or stroke, and this has expanded their targetable patient pool. According to the data published by American College of Cardiology in March 2025, close to 50% of heart failure patients in the U.S. are currently taking ACE inhibitors. This increasing rate of clinical recommendation and use reflects growing physician confidence and experience with ACE inhibitors.
• Among drugs, lisinopril segment is estimated to hold a dominant position in the global angiotensin converting enzymes (ACE) inhibitors market over the forecast period. According to the World Health Organization, Lisinopril has consistently demonstrated higher effectiveness at controlling blood pressure as compared to other ACE inhibitor drugs. It is recommended as a first-line treatment option for hypertension by numerous international clinical practice guidelines. This strong endorsement from the medical community has driven increased adoption by physicians and patients alike over the past decade.
• Among regions, North America is estimated to account for the largest market share in the global angiotensin converting enzymes (ACE) inhibitors market over the forecast period due to higher healthcare spending and affordability of patients in the U.S. According to Centers for Medicare and Medicaid Services, the national healthcare spending in the U.S. reached US$ 4.1 trillion in 2025, accounting for 19.7% of the country's GDP. The availability of favorable reimbursement policies for cardiac conditions, widespread health insurance coverage and presence of major key players have ensured higher adoption rates of ACE inhibitors in the U.S. as compared to other countries.
• Major players operating in the global angiotensin converting enzymes (ACE) inhibitors market include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players